Delisting risk
TScan Therapeutics
Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.
$0.7535
After-hours close+0.00 (+0.15%)
At close$0.7524(+0.29%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.30 | — | — |
| Aug 2026 | −$0.25 | −$0.23 | +9.2% |
| Aug 2026 | −$0.29 | −$0.23 | +20.7% |
| May 2026 | −$0.22 | −$0.22 | 0.0% |
| Mar 2026 | −$0.27 | −$0.18 | +33.3% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.30 | — | — | $1.5M | — | — |
| Aug 12, 2026 | −$0.25 | −$0.23 | +9.2% | $1.9M | $1.1M | −43.9% |
| Aug 11, 2026 | −$0.29 | −$0.23 | +20.7% | $1.9M | $1.1M | −43.9% |
| May 6, 2026 | −$0.22 | −$0.22 | 0.0% | $2.5M | $982.0K | −60.7% |
| Mar 4, 2026 | −$0.27 | −$0.18 | +33.3% | $2.4M | $2.6M | +5.4% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 6, 2025 | ||||||
| Mar 5, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 13, 2024 | ||||||
| Mar 6, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 8, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 9, 2022 | ||||||
| Mar 9, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 19, 2021 | ||||||
| Jul 15, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||